CAMBRIDGE, Mass.—A multiyear collaboration has been announced between Foundation Medicine Inc. and Eisai Co. Ltd. to focus on genomic profiling and diagnostic discovery in a multi-site, international clinical trial of a targeted therapeutic candidate from Eisai. The collaboration will seek to identify genomic alterations in each patient's tumor in order to inform patient stratification, guide drug development decisions and potentially lead to the commercialization of new molecular diagnostics. Though no specific details were released, Foundation Medicine will receive an upfront payment and be eligible for future diagnostic rights.

 

"This collaboration with Foundation Medicine, utilizing their depth of molecular oncology knowledge and ability to partner on a global scale, will help Eisai better understand the genomic makeup of each patient as we work to deliver new targeted treatments that may benefit patients," said Dr. Takashi Owa, chief innovation officer at Eisai.